The interplay between the immunogenic effects of CT (e.g., antigen release) and the tumor’s counteractive PD-L1-driven immunosuppression underscores the rationale for combining CT with immune checkpoint inhibitors in TNBC. The gene discussed is CD274; the disease is neoplasm.